Argent Biopharma (RGT) Stock Statistics & Valuation Metrics

Argent Biopharma has a market cap or net worth of AU$4.22M. The enterprise value is AU$10.41M.

Argent Biopharma has 111,109,580 shares outstanding. The number of shares has decreased by -2.65% in one year.

Argent Biopharma’s return on equity (ROE) is 2.07 and return on invested capital (ROIC) is 4766.67%.

The current PE Ratio of Argent Biopharma is ―. Argent Biopharma’s PEG ratio is 0.00762.

In the last 12 months, Argent Biopharma had revenue of 583.45K and earned -17.84M in profits. Earnings per share was -0.31.

In the last 12 months, operating cash flow was -9.28M and capital expenditures -2.24K, giving a free cash flow of -9.28M billion.

Argent Biopharma pays an annual dividend of ―, resulting in a dividend yield of ―

Argent Biopharma upcoming earnings date is Aug 28, 2026, Before Open (Confirmed).

Argent Biopharma as a current ratio of 0.19, with Debt / Equity ratio of -96.03%

In the past 12 months, Argent Biopharma has paid 0.00 in taxes.

Argent Biopharma EV to EBITDA ratio is -0.70, with an EV/FCF ratio of -1.28.

Argent Biopharma has AU$1.02M in cash and marketable securities with AU$8.29M in debt, giving a net cash position of -AU$7.26M billion.

Gross margin is -413.07%, with operating margin of -2646.84%, and net profit margin of -3058.43%.

The average price target for Argent Biopharma is ―, which is 11.43% higher than the current price. The consensus rating is ―